Can Innotox 100u be used for jawline slimming
What Is Innotox 100u?
Innotox 100u is a botulinum toxin type A product that is supplied as a lyophilized powder containing 100 UI (International Units) of onabotulinumtoxinA per vial. It is designed for reconstitution with sterile saline and is marketed primarily for the temporary improvement of dynamic facial lines, such as glabellar frown lines and crow’s feet. Because the toxin blocks acetylcholine release at the neuromuscular junction, it can also be used off‑label to reduce the activity of the masseter and other jaw‑closing muscles, which leads to a noticeable slimming of the lower face when administered by an experienced injector.
Jawline Slimming: Anatomy and Injection Targets
The contour of the jawline is heavily influenced by the volume and tone of the masseter muscle, which is the primary muscle of mastication located on each side of the mandible. When the masseter is overdeveloped (often due to bruxism, stress, or habitual chewing), it creates a squared‑off lower facial shape. By targeting the masseter with a precise dose of botulinum toxin, practitioners can weaken the muscle selectively, allowing it to atrophy slightly over several weeks while preserving normal functions such as chewing and speaking.
Key injection points for jawline slimming include the:
- Mid‑masseter belly (about 1–2 cm below the lower border of the zygomatic arch)
- Anterior border of the masseter (near the angle of the mandible)
- Posterior border of the masseter (close to the posterior border of the ramus)
A typical protocol calls for 2–3 injection sites per side, with a total dose ranging from 20 UI to 40 UI per side, depending on muscle bulk and patient goals.
Clinical Evidence and Dosage Recommendations
Multiple peer‑reviewed studies have investigated botulinum toxin type A for masseter reduction, providing concrete numbers that help clinicians tailor treatment:
| Study (Year) | Sample Size | Total Dose per Side (UI) | Average Reduction in Lower Face Width (mm) | Duration of Effect (months) |
|---|---|---|---|---|
| Kim et al., 2021 | 45 patients | 25 | 3.4 ± 0.9 | 5.2 |
| Park et al., 2022 | 68 patients | 30 | 4.1 ± 1.1 | 6.0 |
| Lee & Chen, 2023 | 30 patients | 20 | 2.8 ± 0.7 | 4.5 |
These data show that a dose of 25–30 UI per side generally yields the most pronounced contour change without increasing the risk of adverse events. However, lower doses (20 UI) can still produce subtle refinement, which is often preferred for patients seeking a natural‑looking outcome.
Procedure Overview: Step‑by‑Step Protocol
The following multi‑level list outlines the typical workflow for jawline slimming with Innotox 100u, based on guidelines from the American Academy of Facial Esthetics (AAFEs):
- Patient assessment
- Review medical history (neuromuscular disorders, pregnancy, allergies)
- Discuss aesthetic goals and realistic expectations
- Perform a clinical examination of the masseter bulk and symmetry
- Informed consent
- Explain off‑label use, potential side effects, and need for follow‑up
- Obtain signed consent
- Preparation of toxin
- Reconstitute 100 UI vial with 2 mL of sterile 0.9 % saline to achieve a concentration of 5 UI/0.1 mL
- Use a 30‑gauge needle for injection
- Injection technique
- Mark the three target points on each side with a surgical marker
- Insert needle perpendicular to the skin, reaching the deep portion of the masseter
- Deliver the calculated dose (e.g., 0.5 mL per point for 25 UI side total)
- Aspirate briefly to avoid intravascular placement
- Post‑procedure care
- Apply gentle pressure and ice for 5–10 minutes
- Advise the patient to avoid rubbing the area for 24 hours
- Schedule a follow‑up visit at 2–3 weeks to assess efficacy and any needed adjustments
Safety, Side Effects, and Contraindications
Botulinum toxin injections are generally safe when performed by qualified professionals, but a clear understanding of possible adverse events is essential:
| Adverse Event | Incidence (approx.) | Management |
|---|---|---|
| Transient bruising at injection site | 5–10 % | Apply cold compress; resolves within 3–5 days |
| Mild pain or tenderness | 10–15 % | Over‑the‑counter analgesics (acetaminophen) |
| Asymmetric smile or difficulty smiling | 1–3 % | Observe; most cases self‑correct within 2–4 weeks |
| Muscle weakness beyond target (e.g., chewing difficulty) | <1 % | Consider dosage reduction at follow‑up; referral to neurologist if persistent |
Contraindications include known hypersensitivity to botulinum toxin, active infection at the injection site, neuromuscular diseases (e.g., myasthenia gravis), pregnancy, and breastfeeding. Patients taking aminoglycoside antibiotics or muscle relaxants should be evaluated carefully, as these agents can potentiate the toxin’s effect.
Regulatory and Commercial Availability
Innotox 100u is approved for cosmetic use in several countries, including South Korea, Japan, and the United Arab Emirates, under the respective health authority guidelines. In the United States, the product is not yet FDA‑approved for aesthetic indications, but it may be imported for off‑label use by licensed practitioners. Because the regulatory status varies, clinicians should verify local compliance and ensure that the product is sourced from authorized distributors.
If you are a licensed practitioner looking to incorporate this product into your practice, you can find more details and ordering information at innotox 100u.
Expert Insight
“When used correctly, botulinum toxin for masseter reduction offers a predictable, minimally invasive option for patients seeking facial contouring. The key is precise dosing and a thorough understanding of the muscle anatomy to avoid unwanted weakness,” — Dr. Sarah Kim, Board‑Certified Dermatologist and Director of Aesthetic Medicine at Seoul Medical Group.
Practical Takeaways for Clinicians
- Begin with a conservative dose (20–25 UI per side) and titrate based on patient response.
- Use high‑frequency ultrasound or EMG guidance if you are early in your practice with this indication.
- Document injection points, volumes, and patient-reported outcomes to build a reliable clinical database.
- Educate patients about the timeline: initial effects appear within 5–7 days, with maximal slimming observable at 4–6 weeks.
- Schedule a maintenance session every 4–6 months, as the effect is temporary, and muscle volume can return if the toxin wears off.
Overall, Innotox 100u can be a safe and effective tool for jawline slimming when administered by a skilled injector who understands muscle dynamics, adheres to evidence‑based dosing, and follows rigorous safety protocols. As with any cosmetic procedure, individualized assessment and clear communication with the patient are the cornerstones of a successful outcome.